Perth biotech Botanix to raise $70m following FDA nod for sweat-stopper gel

‘Transformative event’: Clinical dermatology firm Botanix gets US FDA nod for sweat-stopper gel

thewest.com.au - 20/Jun 02:30

Clinical dermatology company Botanix has secured US Food and Drug Administration approval for its gel aimed at treating excessive sweating.

FDA Approves Sofdra (sofpironium) Topical Gel for the Treatment of Primary Axillary Hyperhidrosis

drugs.com - 20/Jun 04:06

Philadelphia and Phoenix US, 20 June 2024 -- Clinical dermatology company, Botanix Pharmaceuticals Ltd. (ASX:BOT, Botanix or the Company), is pleased...

Radiopharm soars on $70m funding for cancer treatment

thewest.com.au - 25/Jun 04:41

Radiopharm Theranostics’ stock rocketed up 35 per cent this morning after the cancer-fighting company secured commitments from leading investors to...

ASX Health Stocks: Control Bionics surges over 50pc after TGA approval of DROVE wheelchair

stockhead.com.au - 20/Jun 00:53

Control Bionics' shares surge after TGA approval, and Botanix Pharma granted US FDA approval for Sofdra (sofpironium) gel. ...

PharmAust raises cash for anti-cancer study

aumanufacturing.com.au - 23/Jun 16:07

Clinical stage biotechnology company PharmAust has received commitments to raise $10 million via an institutional placement with directors and...

Monthly News Roundup - June 2024

drugs.com - 30/Jun 00:06

FDA Grants Expanded Approval to Skyrizi for Ulcerative Colitis On June 18th, the U.S. Food and Drug Administration (FDA) approved AbbVie’s...

Imricor starts global trial for US FDA approval

stockhead.com.au - 21/Jun 04:48

Imricor’s VISABL-AFL global clinical trial supporting US Food and Drug Administration (FDA) approval has kicked off. ...

Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab

zacks.com - 12:34

Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the...

Sarepta Therapeutics Announces Expanded US FDA Approval of Elevidys to Duchenne Muscular Dystrophy Patients Ages 4 and Above

drugs.com - 20/Jun 23:06

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 20, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare...

Eli Lilly expects FDA decision on weight loss drug Zepbound for sleep apnea as early as end of the year

asianewsday.com - 21/Jun 20:29

Eli Lilly on Friday said it applied for U.S. approval of its weight loss drug Zepbound for the treatment of the most common sleep-related breathing...

Rubriques :